A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial

Eric S Kilpatrick, Alan S Rigby, Stephen L Atkin, Eric S Kilpatrick, Alan S Rigby, Stephen L Atkin

Abstract

Objective: Debate remains as to whether short- or long-term glycemic instability confers a risk of microvascular complications in addition to that predicted by mean glycemia alone. In this study, we analyzed data from the Diabetes Control and Complications Trial (DCCT) to assess the effect of A1C variability on the risk of retinopathy and nephropathy in patients with type 1 diabetes.

Research design and methods: A1C was collected quarterly during the DCCT in 1,441 individuals. The mean A1C and the SD of A1C variability after stabilization of glycemia (from 6 months onwards) were compared with the risk of retinopathy and nephropathy with adjustments for age, sex, disease duration, treatment group, and baseline A1C.

Results: Multivariate Cox regression showed that the variability in A1C added to mean A1C in predicting the risk of development or progression of both retinopathy (hazard ratio 2.26 for every 1% increase in A1C SD [95% CI 1.63-3.14], P < 0.0001) and nephropathy (1.80 [1.37-2.42], P < 0.0001), with the relationship a feature in conventionally treated patients in particular.

Conclusions: This study has shown that variability in A1C adds to the mean value in predicting microvascular complications in type 1 diabetes. Thus, in contrast to analyses of DCCT data investigating the effect of short-term glucose instability on complication risk, longer-term fluctuations in glycemia seem to contribute to the development of retinopathy and nephropathy in type 1 diabetes.

Figures

Figure 1
Figure 1
Relative risk of retinopathy progression over the range of patients within the 0–97.5th centile of mean A1C after adjusting for A1C SD, using the 2.5th centile as a reference (A) and for A1C SD after adjustment for mean A1C (B).

References

    1. Monnier L, Colette C: Glycemic variability: should we and can we prevent it? Diabetes Care 31:150–154, 2008
    1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986, 1993
    1. The Diabetes Control and Complications Trial Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44:968–983, 1995
    1. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853, 1998
    1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412, 2000
    1. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295:1707–1708, 2006
    1. Service FJ, O'Brien PC: The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia 44:1215–1220, 2001
    1. Kilpatrick ES, Rigby AS, Atkin SL: The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490, 2006
    1. Kilpatrick ES, Rigby AS, Atkin SL: Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in type 1. Diabetologia 51:365–371, 2008
    1. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN: The effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial—revisited. Diabetes 57:995–1001, 2008
    1. Kilpatrick ES, Rigby AS, Atkin SL: Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control. Clin Chem 53:897–901, 2007
    1. Prince C, Becker D, Costacou T, Miller R, Orchard T: Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50:2280–2288, 2007
    1. The Diabetes Control and Complications Trial Research Group: Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care 23:1084–1091, 2000
    1. Schemper M, Henderson R: Predictive accuracy and explained variation in Cox regression. Biometrics 56:249–255, 2000
    1. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A: Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52:2795–2804, 2003
    1. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J-P, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681–1687, 2006
    1. Wentholt I, Kulik W, Michels R, Hoekstra J, DeVries J: Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 51:183–190, 2008
    1. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C: In vivo formation of 8-iso-prostaglandin F2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99:224–229, 1999
    1. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569, 2002
    1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653, 2005
    1. Ihnat M, Thorpe J, Ceriello A: Hypothesis: the ‘metabolic memory,’ the new challenge of diabetes. Diabet Med 24:582–586, 2007
    1. The Kroc Collaborative Study Group: Blood glucose control and the evolution of diabetic-retinopathy and albuminuria: a preliminary multicenter trial. N Engl J Med 311:365–372, 1984
    1. The Diabetes Control and Complications Trial Research Group: Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874–886, 1998
    1. Smith LEH, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276:1706–1709, 1997
    1. McCarter RJ, Hempe JM, Chalew SA: Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 29:352–355, 2006

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere